Clinical trial · Expanded Access
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
NCT04135092CI-TRIAL-00046989no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Single Patient Expanded Access
Conditions
Conditions (0)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Data not yet available
No condition recorded.
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aldesleukin | Drug | Aldesleukin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Fludarabine | Drug | Fludarabine | ALIAS |
| Individual Patient TCR Transduced PBL | Biological | — | UNRESOLVED |
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
Eligibility
Eligibility (as posted)
Show eligibility criteria text
Inclusion Criteria: * Measurable (per RECIST v1.1 criteria), metastatic prostate cancer. * Refractory to approved standard systemic therapy. * Ability of subject to understand and the willingness to sign a written informed consent document. * Willing to sign a Durable Power of Attorney Form. * Willing to practice birth control from the time of enrollment on this study and for four months after treatment. * Subject must be co-enrolled on protocol 03-C-0277. Exclusion Criteria: Not applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.